US Patent Issued to AstraZeneca on Nov. 11 for "Osimertinib for use in the treatment of non-small cell lung cancer" (British Inventor)

ALEXANDRIA, Va., Nov. 11 -- United States Patent no. 12,465,608, issued on Nov. 11, was assigned to AstraZeneca AB (Sodertalje, Sweden).

"Osimertinib for use in the treatment of non-small cell lung cancer" was invented by Anthony Francis Patrick Nash (Cambridge, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of EGFR TKI-naive patients with locally-advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy."

The patent was filed on March 27, 2020, under ...